№ files_lp_4_process_3_097146
File format: docx
Character count: 1969
File size: 26 KB
Clinical genetics documentation template outlining elements used to justify the medical necessity of exome sequencing based on patient history, differential diagnosis, clinical management implications, and genetic counseling considerations.
Language:
English
Document Type:
Clinical documentation template
Medical Field:
Medical genetics
Subject:
Justification of medical necessity for exome sequencing
Purpose:
Clinical justification for ordering exome testing
Healthcare Context:
Diagnostic evaluation of patients with suspected genetic conditions
Test Type:
Exome sequencing
Clinical Components:
Patient medical history, family history, differential diagnosis, clinical management considerations
Clinical Actions Referenced:
Medication changes, dietary modifications, procedural or surveillance adjustments
Genetic Counseling Elements:
Inheritance education, recurrence risk assessment, prenatal diagnosis discussion
Patient Considerations:
Individuals with complex or unexplained clinical features suggesting genetic disease
Family Considerations:
Impact on relatives and reproductive planning
Post-Test Activity:
Follow-up genetic counseling after results disclosure
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Region / City:
N/A
Topic:
Genetic Testing, Exome Sequencing
Document Type:
Letter
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Healthcare providers, medical practitioners
Validity Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Section:
Supplemental Materials
Abbreviations:
IOP; MEE/RHC; QC; GSA; PCA; LD; MAF; PC; WES; BAM; VCF; EUR; AFR; AMR; EAS; SAS; GQ; SNPs; MAD; GTEx; Non-PAR; Indels; HWE; AB; GWAS; FAME; GC; QTL; eQTL; CLPP; FDR; OHTN; RINT
Methodology:
Whole exome sequencing and statistical genetic analysis
Sequencing Platform:
NovaSeq S4 flow cell (2x151bp)
Library Preparation Kit:
KAPA Hyper Prep with Library Amplification Primer Mix (KK8504)
Capture Kit:
IDT XGen hybridization and wash kit
Custom Bait:
TWIST Biosciences exome bait
Liquid Handling Systems:
Agilent Bravo; Hamilton Starlet
Quantification Method:
qPCR; Invitrogen Quant-It broad range dsDNA assay
Genotyping Platform:
Global Screening Array (GSA)
Software:
PLINK 1.9; PLINK 2.0; R; Python; Hail v0.2
Reference Panel:
1000 Genomes Project Phase 3
Ancestry Groups:
European (EUR); African (AFR); Admixed American (AMR); East Asian (EAS); South Asian (SAS)
Statistical Analysis:
Analysis of variance (aov in R); Tukey honest significant difference test
Quality Control Criteria:
Sample-level and variant-level QC including genotype missingness, heterozygosity, relatedness (PI_HAT), sex concordance, ancestry inference, BAM and VCF metrics
Note:
Year
Topic:
Exome sequencing data
Document Type:
Statistical report
Target Audience:
Researchers, geneticists
Year:
2017
Region / City:
N/A
Topic:
Genomic research, whole exome sequencing
Document Type:
Research Table
Author:
N/A
Target Audience:
Researchers, geneticists
Period of validity:
N/A
Date of approval:
N/A
Date of modifications:
N/A
OMIM Phenotypes:
Nephrotic syndrome, Gaucher disease, Cardiomyopathy, and others
Related pathways:
SOX9 biological pathway, transcription factors
Note:
Year
Theme:
Medical Equipment, Adaptive Devices
Document Type:
Medical Necessity Letter
Target Audience:
Insurance Providers, Medical Professionals
Organization:
Driscoll Health Plan
Document type:
Clinical policy and administrative guidelines
Revision date:
November 1, 2024
Geographic scope:
Texas
Programs referenced:
STAR, STAR Kids, CHIP
Subject area:
Therapy services prior authorization and medical necessity
Target audience:
Therapy providers and referring physicians
Authorization method:
Provider web portal and fax submission
Related forms:
Texas Standard Prior Authorization Request Form for Health Care Services (TARF), Therapy Referral Review by Ordering Physician Attestation Form
Effective policy elements:
Initial evaluations, re-evaluations, continuation of therapy, start of care rules
Coverage criteria:
Medical necessity based on clinical documentation
Source type:
Health plan policy guideline
Year:
2021
Region / City:
United States
Topic:
Medical Necessity Letter, Health Treatment
Document Type:
Medical Document
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, healthcare providers
Period of validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2021
Region / City:
California, Arizona
Topic:
Energy Transmission, Public Utilities
Document Type:
Decision
Organization / Institution:
California Public Utilities Commission
Author:
California Public Utilities Commission
Target Audience:
Stakeholders in energy infrastructure and transmission
Effective Period:
N/A
Approval Date:
November 4, 2021
Date of Changes:
N/A
Year:
2025
Region / City:
United States
Theme:
Medical necessity letter
Document type:
Medical letter
Organization / Institution:
Takeda Pharmaceuticals U.S.A., Inc.
Author:
Takeda Pharmaceuticals U.S.A., Inc.
Target audience:
Physicians, insurance providers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Note:
Date
Diagnosis:
G36.0, neuromyelitis optica [Devic]
Treatment:
UPLIZNA® (inebilizumab-cdon), injection, 1 mg
Reason for request:
Medical necessity for treatment of neuromyelitis optica spectrum disorder (NMOSD) with UPLIZNA
Enclosures:
Prescribing Information, clinical notes, FDA approval letter, patient relapse history, test results, etc.
Year:
2024
Region / City:
United States
Topic:
Medical Necessity Letter
Document Type:
Medical Letter
Organization / Institution:
Bausch + Lomb
Author:
Physician
Target Audience:
Healthcare providers, Payers
Action Period:
June 2024
Approval Date:
June 2024
Modification Date:
N/A
Document type:
Medical necessity letter
Therapeutic area:
Ophthalmology
Indication:
Reduction of intraocular pressure in open-angle glaucoma or ocular hypertension
Medication name:
VYZULTA (latanoprostene bunod ophthalmic solution)
Dosage strength:
0.024%
Drug class:
Prostaglandin analogue with nitric oxide–donating activity
Regulatory status:
FDA-approved prescription medication
Manufacturer:
Bausch & Lomb Inc.
Intended recipient:
Health insurance payer or medical director
Target population:
Patients with open-angle glaucoma or ocular hypertension
Clinical evidence referenced:
Phase 2 VOYAGER study; Phase 3 APOLLO and LUNAR studies; real-world retrospective studies
Safety information included:
Yes
References:
Peer-reviewed journals and prescribing information
Source type:
Industry-provided informational material
Year:
2025
Region / City:
Princeton, NJ
Theme:
Medical necessity documentation
Document Type:
Medical letter
Organization / Institution:
Bristol-Myers Squibb Company
Author:
<>
Target Audience:
Healthcare professionals, physicians
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2025
Jurisdiction:
West Virginia, United States
Type of document:
Legislative Act
Governing body:
West Virginia Legislature
Authors:
Delegates Riley, Linville, D. Cannon, Eldridge
Effective date:
April 11, 2025
Subject:
Public utilities regulation, water and sewer services, certificate of public convenience and necessity
Legal references:
§24-2-11, §31-15A-1 et seq. of the West Virginia Code
Scope:
Construction projects of water and sewer services for utilities with at least 4,500 customers and $3 million or more in annual revenues
Approval authority:
Public Service Commission, Infrastructure and Jobs Development Council
Decision timelines:
Standard projects 225–270 days, projects >$50 million 400 days
Year:
2023
Region / City:
United States
Subject:
Healthcare
Document Type:
Template
Institution / Organization:
Takeda Oncology
Author:
Takeda Oncology
Target Audience:
Healthcare providers, insurance companies
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Note:
Date
Year:
2026
Region / City:
N/A
Topic:
Genetic Testing, Exome Sequencing
Document Type:
Letter
Organization / Institution:
N/A
Author:
N/A
Target Audience:
Healthcare providers, medical practitioners
Validity Period:
N/A
Approval Date:
N/A
Modification Date:
N/A
Program:
Illinois Early Intervention Program
State:
Illinois
Type of document:
Administrative form
Subject area:
Early intervention services
Focus:
Assistive technology justification
Target population:
Infants and toddlers enrolled in Early Intervention
Associated plan:
Individualized Family Service Plan (IFSP)
Required contributors:
Early Intervention evaluator, service coordinator, physician
Required approvals:
Physician signature
Content sections:
Demographic information, provider information, IFSP details, assessment and justification
Purpose:
Documentation of developmental necessity for assistive technology items
Note:
Year
Topic:
Medical Nutrition
Document Type:
Template Letter
Organization / Institution:
Abbott Nutrition
Author:
Physician
Target Audience:
Health Insurance Providers
Year:
2026
Organization:
U.S. Department of Labor, Occupational Safety and Health Administration
Type of document:
Agreement template / Memorandum of understanding
Subject:
Alliance Program Ambassador relationship
Legal status:
Non-binding
Effective date:
Upon signing
Expiration:
Duration of cooperative association, subject to 30-day termination notice
Contact:
[email protected]
OMB Control Number:
1218-0274